Articles tagged with: Adriamycin
News»
Results from a small Phase 2 study conducted throughout Japan suggest that a combination of Velcade, doxorubicin, and intermediate-dose dexamethasone is effective in patients with relapsed or refractory multiple myeloma.
Most patients (89 percent) responded to treatment, with a third of them achieving a complete or near complete response. In addition, the median progression-free survival was 12.1 months.
According to the Japanese researchers, the findings from this study are comparable to those from previous studies that examined the effectiveness of the Velcade (bortezomib), doxorubicin (Adriamycin), and
NewsFlash »
INNO-206 Shows Activity Against Myeloma - Results of a preclinical study show that the investigational drug INNO-206 inhibits blood vessel formation and reduces cell growth in myeloma cell lines. The drug showed these effects when tested alone; additionally it enhanced the efficacy of Velcade (bortezomib) when tested in combination. INNO-206 is a derivative of the chemotherapy agent doxorubicin (Adriamycin). This study also showed that INNO-206 was safer in mice than doxorubicin and therefore could be administered at higher doses. For information, please see the study in Clinical Cancer Research (abstract).
TRAIL-Doxorubicin Combination May Eradicate Myeloma Cells – Results of a preclinical study show that a combination of doxorubicin and TRAIL, a protein that induces cell death, was able to eradicate myeloma cell lines. In particular, the TRAIL-doxorubicin combination successfully eliminated cells that are implicated in tumor initiation as well as tumor growth. According to the study investigators, these findings offer a promising new approach to finding a cure for multiple myeloma. For more information, please see the study in PloS One.
Relatives Of Multiple Myeloma Patients Have Increased Risk Of MGUS – Results of a study conducted at the Mayo Clinic indicate that first-degree relatives of multiple myeloma patients are 3.4 times as likely to develop light-chain monoclonal gammopathy of undetermined significance (MGUS) compared to the general population. A previous study also showed that these relatives are at an increased risk of developing heavy-chain MGUS. For more information, please see the study in the British Journal of Hematology (abstract).
IMF Myeloma Workshop For Patients And Families – The International Myeloma Foundation (IMF) will be hosting a workshop for multiple myeloma patients and their families on June 23 in Milwaukee, WI. Dr. Ayman Saad from the Medical College of Wisconsin, Dr. Natalie Callander from the University of Wisconsin School of Medicine, and nurse Tiffany Richards from the MD Anderson Cancer Center in Houston will speak about topics including treatment options, managing side effects, and local clinical trials. For more information or to register, please visit the IMF website.
For a more detailed listing of myeloma-related events, please check the Myeloma Beacon Events Calendar.
News»
The results of a recent Japanese study suggest that a vincristine-doxorubicin-dexamethasone regimen without intermittent high-dose dexamethasone reduces the risk of bacterial infection in multiple myeloma patients without affecting the treatment’s efficacy.
Based on these findings, the study authors recommended avoiding the administration of intermittent high-dose dexamethasone with the vincristine-doxorubicin-dexamethasone regimen in myeloma patients at high risk for infection.
The combination treatment of vincristine (Oncovin), doxorubicin (Adriamycin), and dexamethasone (Decadron) plus high-dose pulses of dexamethasone (referred to as VAD-HD) was first approved as a treatment for advanced multiple myeloma.
It …
News»
The results of a recent Phase 2 trial indicate that Velcade-doxorubicin-dexamethasone treatment can reverse multiple myeloma-associated kidney damage in myeloma patients suffering from kidney failure. The regimen also improved patients’ disease statuses and was associated with few severe side effects.
Multiple myeloma affects plasma cells, a subset of white blood cells that fight infections by producing antibody. In multiple myeloma patients, cancerous plasma cells produce one kind of abnormal antibody.
In some myeloma patients, this abnormal antibody binds to a protein produced in the kidney. These antibody-protein complexes then accumulate in the …
